Australia’s Health Minister, Mark Butler, has welcomed interim advice from the National Health and Medical Research Council (NHMRC) which found that puberty suppressants can be an appropriate treatment option for young people experiencing gender incongruence.
“The Australian Government believes in a strong health system for all Australians. We want young people and their families to receive the best healthcare, led by the best available evidence,” Butler said in a statement.

The minister said governments also have a clear responsibility to ensure Australians receive the best medical advice and care available, and that responsibility is especially important when it comes to the care of highly vulnerable children and adolescents.
“That’s why last year I asked the National Health and Medical Research Council (NHMRC) to undertake a comprehensive review of the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents in Australia, and to develop new national guidelines.
“The NHMRC is the nation’s leading expert body in health and medical research and has a statutory responsibility for developing and supporting high-quality clinical practice guidelines.”
The minister said the NHMRC’s advice was developed in line with established guideline development processes and international best-practice methodology.
It was underpinned by a systematic review of evidence and informed by the expertise of clinicians, researchers and Australians with lived experience.
“The NHMRC advises that puberty suppressants can be considered as a treatment option in the care of trans and gender-diverse people aged under 18. However, it is not a one-size-fits-all decision and may not be desired by, or appropriate for, all young people accessing care.
“Decisions about treatment with puberty suppressants should be informed by the provision of appropriate information to the young person and their parents or carers, a comprehensive health assessment, multidisciplinary input tailored by a healthcare team to the needs of the young person, and regular monitoring.”
Headspace Welcomes Announcement
National CEO of mental health organisation Headspace, Jason Trethowan, welcomed the announcement.
“The interim guidelines affirm what we know: puberty suppression should remain a treatment option for trans and gender-diverse young people. Headspace also knows that gender-affirming care can significantly improve mental health outcomes and save lives.
“Today’s interim guidelines reinforce that evidence-informed healthcare should continue to guide decisions about care.”
Trethowan said decisions about care should be made on an individual basis by young people, their families and appropriately qualified healthcare professionals.
“We know trans and gender-diverse young people experience disproportionately high rates of anxiety, depression, self-harm and suicidal distress.
“Puberty suppression is an evidence-informed treatment option, delivered following careful clinical assessment of a young person’s individual needs, that can support their mental health and wellbeing.”
The mental health advocate said some public discussion around healthcare for transgender young people had been harmful.
“Some of the recent public conversations around gender-affirming care have had a harmful impact on many trans and gender-diverse young people. Too often, these conversations spread misinformation, reinforce stigma and add to the distress that young people are already experiencing.
“We hope today’s release of the interim guidelines sends a message to trans and gender-diverse young people and their families that they deserve access to care that is guided by evidence, informed by expert clinical judgement, delivered safely and centred on their wellbeing. There is still more work to do to ensure trans and gender-diverse young people can access the care, support and affirmation they need.”

AusPATH and LGBTIQ+ Health Australia welcome advice
Nicky Bath, CEO of LGBTIQ+ Health Australia (LHA), welcomed the advice as an important validation of evidence-based clinical practice in Australia.
“The NHMRC is one of Australia’s most respected health and medical institutions, with responsibility for developing evidence-informed guidance across a broad range of health areas. Its processes are recognised for their rigour, independence and commitment to scientific evidence.
“The strength of this advice lies in the expertise behind it. The committee brought together clinical experts, researchers and people with lived experience to carefully consider the evidence and its implications for young people and their families. That gives confidence that the advice is both rigorous and reflective of the evidence and lived experience.”
Eloise Brook, CEO of AusPATH, said the advice provides a critical update to Australia’s established approach to gender-affirming healthcare for young people.
“The advice recognises that puberty suppressants can be a treatment option in the care of people aged under 18 with gender incongruence. The use of puberty suppressants is one possible part of care, not the entirety of care, and it is not necessary to wait until a young person is distressed before providing care.
“The Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, developed by the Royal Children’s Hospital Melbourne, provide an important framework for clinical practice in Australia. The NHMRC’s interim advice is a valuable addition that supports continuing evidence-informed decision-making, clinical governance and high-quality care. It reflects the ongoing evolution of clinical practice and healthcare guidance in gender-affirming care, consistent with clinical guideline development processes across all areas of health.
“As with all NHMRC guidelines, recommendations are informed by the best available evidence and are updated as new evidence emerges. This advice provides an important foundation for continued evidence review, clinical excellence and high-quality care.
“It is important that the current standards remain the foundation of care while the NHMRC progresses its work towards comprehensive national guidelines, with the interim advice contributing to and sitting alongside existing best-practice approaches.”





